Table 1 Clinical characteristics of subjects according to CKD stage
Total | CKD stage 1–2 | CKD 3a | CKD 3b–5 | ||
|---|---|---|---|---|---|
Variable | N=139 | n=85 | n=27 | n=27 | P-value for trend |
Age (years) | 44±17 | 37±16 | 51±10 | 57±14 | <0.0001 |
Male | 84 (60) | 46 (54) | 20 (74) | 18 (66) | 0.13 |
Body mass index (kg m−2) | 24±4 | 23±4 | 24±3 | 24±4 | 0.4 |
Hypertension | 69 (49) | 29 (34) | 20 (74) | 20 (74) | <0.0001 |
Diabetes mellitus | 13 (9) | 6 (7) | 2(7) | 5 (18) | 0.18 |
Dyslipidemia | 83 (59) | 46 (54) | 19 (70) | 18 (66) | 0.23 |
Hyperuricemia | 64 (46) | 21 (24) | 21 (77) | 22 (81) | <0.0001 |
Ever smoking status | 60 (43) | 31 (36) | 16 (59) | 13 (48) | 0.09 |
Mean blood pressure (mm Hg) | 89±10 | 85±9 | 96±9 | 93±10 | <0.0001 |
Serum creatinine (mg dl−1) | 1.0±0.6 | 0.7±0.1 | 1.0±0.1 | 1.8±1.0 | <0.0001 |
eGFR (ml min−1 per 1.73 m2) | 73±31 | 92±23 | 53±3 | 31±8 | <0.0001 |
LDL cholesterol (mg dl−1) | 117±53 | 119±55 | 121±56 | 108±40 | 0.61 |
Fasting glucose (mg dl−1) | 105±31 | 102±27 | 106±24 | 113±44 | 0.24 |
HbA1c (%) | 5.5±0.6 | 5.5±0.6 | 5.5±0.3 | 5.8±0.9 | 0.09 |
UA (mg dl−1) | 6.3±1.7 | 5.7±1.4 | 7.0±1.5 | 7.2±1.9 | <0.0001 |
hs-CRP(mg l−1) | 0.9 (0.3–2.1) | 0.6 (0.2–2.0) | 1.5 (0.7–2.9) | 1.4 (0.6–2.1) | 0.05 |
FMD (%) | 5.9±2.9 | 6.6±3.0 | 4.7±2.6 | 5.0±2.4 | 0.003 |
Baseline brachial artery diameter (mm) | 3.8±0.6 | 3.7±0.6 | 4.1±0.6 | 3.9±0.5 | 0.001 |
SA-IT index | 1.1±0.9 | 0.8±0.8 | 1.4±0.8 | 1.7±0.6 | <0.0001 |
Antihypertensive drugs | 65 (46) | 26 (30) | 19 (70) | 20 (74) | <0.0001 |
Renin–angiotensin system inhibitors | 58 (41) | 24 (28) | 15 (55) | 19 (70) | 0.0002 |
Calcium channel blockers | 29 (20) | 11 (12) | 10 (37) | 8 (29) | 0.02 |
Diuretics | 11 (7) | 8 (9) | 2 (7) | 1 (3) | 0.6 |
Others | 12 (13) | 4 (4) | 4 (14) | 4 (14) | 0.1 |
Statins | 19 (13) | 8 (9) | 3 (11) | 8 (29) | 0.02 |
Antiuricemic drugs | 21 (15) | 3 (3) | 6 (22) | 12 (44) | <0.0001 |
